Amalgamated Bank Cuts Stake in Enovis Corporation (NYSE:ENOV)

Amalgamated Bank lessened its stake in shares of Enovis Corporation (NYSE:ENOV - Free Report) by 33.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 17,135 shares of the company's stock after selling 8,752 shares during the quarter. Amalgamated Bank's holdings in Enovis were worth $655,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Aster Capital Management DIFC Ltd acquired a new stake in shares of Enovis during the fourth quarter worth $29,000. Quadrant Capital Group LLC boosted its holdings in shares of Enovis by 53.0% during the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock worth $30,000 after purchasing an additional 239 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Enovis by 266.7% during the first quarter. Farther Finance Advisors LLC now owns 737 shares of the company's stock worth $27,000 after purchasing an additional 536 shares during the last quarter. Quarry LP boosted its holdings in shares of Enovis by 506.1% during the fourth quarter. Quarry LP now owns 897 shares of the company's stock worth $39,000 after purchasing an additional 749 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Enovis by 144.8% during the first quarter. GAMMA Investing LLC now owns 1,170 shares of the company's stock worth $45,000 after purchasing an additional 692 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company's stock.

Enovis Trading Down 5.3%

Shares of ENOV traded down $1.91 during trading hours on Friday, hitting $34.03. The stock had a trading volume of 992,363 shares, compared to its average volume of 903,586. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.32 and a current ratio of 2.55. The firm has a market cap of $1.94 billion, a P/E ratio of -2.44 and a beta of 1.70. The company's fifty day simple moving average is $32.98 and its 200 day simple moving average is $37.64. Enovis Corporation has a 12-month low of $28.83 and a 12-month high of $49.83.

Enovis (NYSE:ENOV - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.07. Enovis had a positive return on equity of 5.99% and a negative net margin of 37.65%. The business had revenue of $558.83 million for the quarter, compared to analyst estimates of $558.80 million. During the same period last year, the company posted $0.50 EPS. The business's quarterly revenue was up 8.2% on a year-over-year basis. Equities research analysts forecast that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on ENOV. JMP Securities decreased their price objective on Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. Needham & Company LLC decreased their price objective on Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Canaccord Genuity Group decreased their price objective on Enovis from $75.00 to $70.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Finally, Evercore ISI cut their target price on Enovis from $48.00 to $46.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Enovis has an average rating of "Moderate Buy" and a consensus target price of $55.60.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.